Derek J. Maetzold Sells 22,639 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek J. Maetzold sold 22,639 shares of the firm’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $20.12, for a total value of $455,496.68. Following the sale, the insider now directly owns 80,465 shares of the company’s stock, valued at approximately $1,618,955.80. This represents a 21.96 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Castle Biosciences Stock Performance

Shares of Castle Biosciences stock opened at $18.76 on Friday. The company has a quick ratio of 7.64, a current ratio of 7.78 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a 12 month low of $16.97 and a 12 month high of $35.84. The business has a fifty day simple moving average of $25.99 and a 200-day simple moving average of $28.70. The stock has a market cap of $525.41 million, a PE ratio of 93.80 and a beta of 0.98.

Institutional Trading of Castle Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of CSTL. US Bancorp DE raised its holdings in shares of Castle Biosciences by 1,889.2% during the third quarter. US Bancorp DE now owns 4,615 shares of the company’s stock worth $132,000 after acquiring an additional 4,383 shares in the last quarter. Principal Financial Group Inc. raised its holdings in shares of Castle Biosciences by 2.7% during the third quarter. Principal Financial Group Inc. now owns 1,538,520 shares of the company’s stock worth $43,879,000 after acquiring an additional 40,377 shares in the last quarter. Assetmark Inc. raised its holdings in shares of Castle Biosciences by 16.8% during the third quarter. Assetmark Inc. now owns 5,212 shares of the company’s stock worth $149,000 after acquiring an additional 748 shares in the last quarter. Lisanti Capital Growth LLC raised its holdings in shares of Castle Biosciences by 60.2% during the third quarter. Lisanti Capital Growth LLC now owns 154,710 shares of the company’s stock worth $4,412,000 after acquiring an additional 58,160 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in shares of Castle Biosciences during the third quarter worth $1,478,000. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on CSTL. Robert W. Baird raised their target price on Castle Biosciences from $36.00 to $37.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th. Stephens reaffirmed an “overweight” rating and issued a $41.00 target price on shares of Castle Biosciences in a research report on Thursday, January 2nd. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $40.00.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.